内容紹介
A Case of Complete Response(CR)to S-1 and Paclitaxel(PTX)Combination Therapy in a Patient with Unresectable Gastric Cancer
Summary
We report a case of a patient with unresectable gastric cancer who showed complete response(CR)to S-1 and paclitaxel(PTX)combination therapy. The patient(a 67-year-old woman)was diagnosed with unresectable advanced gastric cancer with metastases in the Virchow's lymph nodes and para-aortic lymph nodes. Systemic chemotherapy with 70 mg/m2 S-1(days 1-14)and 70 mg/m2 PTX(day 1)was administered every 3 weeks. At the end of 7 courses of chemotherapy, the primary lesion and swollen lymph nodes became markedly smaller. After 7 courses, an additional 39 courses were administered over 2.5 years. No notable adverse events were seen, and the patient's performance status(PS)was 0. CR was monitored by imaging studies. No cancer cells were detected on cytological examination of the primary lesion. Monotherapy with 70 mg/m2 S-1(days 1-28, 2-week drug holiday)has been administered for the past 3 years. The patient is currently treated as an outpatient and maintains CR and a PS of 0.
要旨
S-1+paclitaxel(PTX)併用療法にてcomplete response(CR)を得た切除不能胃癌の1例を経験した。症例は67歳,女性。Virchowリンパ節・傍大動脈リンパ節転移陽性の切除不能胃癌と診断された。induction chemotherapyの方針となり,S-1 70 mg/m2(day 1～14)+PTX 70 mg/m2(day 1)の3週毎投与を開始したところ,7コース終了時点で原発巣・腫大リンパ節の著明な縮小を認めた。以後2年6か月間に計39コース施行したが,PS 0,画像上CRを維持し原発巣の生検にても癌細胞は認めなかった。その後S-1単剤療法(day 1～28,2週休薬)70 mg/m2に変更し,治療開始より3年経過しているがCR,PS 0を維持して外来治療継続中である。
目次
Summary
We report a case of a patient with unresectable gastric cancer who showed complete response(CR)to S-1 and paclitaxel(PTX)combination therapy. The patient(a 67-year-old woman)was diagnosed with unresectable advanced gastric cancer with metastases in the Virchow's lymph nodes and para-aortic lymph nodes. Systemic chemotherapy with 70 mg/m2 S-1(days 1-14)and 70 mg/m2 PTX(day 1)was administered every 3 weeks. At the end of 7 courses of chemotherapy, the primary lesion and swollen lymph nodes became markedly smaller. After 7 courses, an additional 39 courses were administered over 2.5 years. No notable adverse events were seen, and the patient's performance status(PS)was 0. CR was monitored by imaging studies. No cancer cells were detected on cytological examination of the primary lesion. Monotherapy with 70 mg/m2 S-1(days 1-28, 2-week drug holiday)has been administered for the past 3 years. The patient is currently treated as an outpatient and maintains CR and a PS of 0.
要旨
S-1+paclitaxel(PTX)併用療法にてcomplete response(CR)を得た切除不能胃癌の1例を経験した。症例は67歳,女性。Virchowリンパ節・傍大動脈リンパ節転移陽性の切除不能胃癌と診断された。induction chemotherapyの方針となり,S-1 70 mg/m2(day 1～14)+PTX 70 mg/m2(day 1)の3週毎投与を開始したところ,7コース終了時点で原発巣・腫大リンパ節の著明な縮小を認めた。以後2年6か月間に計39コース施行したが,PS 0,画像上CRを維持し原発巣の生検にても癌細胞は認めなかった。その後S-1単剤療法(day 1～28,2週休薬)70 mg/m2に変更し,治療開始より3年経過しているがCR,PS 0を維持して外来治療継続中である。